Healthcare business remains loss-making

「Sales of the IT Hanabiratake product have lagged behind plan, leaving revenue broadly flat at ¥55 million, or 100.8% of the year-earlier level. In terms of earnings, the segment loss deteriorated slightly to ¥25 million from ¥24 million a year earlier.」

「Sales of the IT Hanabiratake product as a food with function claims have lagged behind plan, resulting in revenue of ¥55 million, or 94.5% of the year-earlier level. In terms of earnings, the segment loss deteriorated slightly to ¥24 million from ¥22 million a year earlier owing to the effect of lower revenue and other factors.」

「Revenue from OEM production of maitake products declined from a year earlier, resulting in lower revenue of ¥105 million, or 73.2% of the year-earlier level. In terms of earnings, the segment loss deteriorated slightly to ¥51 million from ¥37 million a year earlier owing to the effect of lower revenue.」

「Revenue from OEM production of maitake products declined from a year earlier, resulting in lower revenue of ¥58 million, or 77.4% of the year-earlier level. In terms of earnings, despite the effect of lower revenue, the segment loss was limited to a slight deterioration, widening from ¥19 million a year earlier to ¥22 million, owing to reductions in selling, general and administrative expenses, including research and development costs.」

「Revenue from OEM production of maitake products declined from a year earlier, resulting in lower revenue of ¥31 million, or 82.0% of the year-earlier level. In terms of earnings, the segment loss widened from ¥9 million a year earlier to ¥11 million owing to the effect of lower revenue.」

「Strong sales of high-margin raw materials, together with continued efforts to reduce expenses, improved the segment loss to ¥37 million from ¥51 million in the previous fiscal year.」

「Third-quarter revenue declined to ¥103 million, or 97.9% of the year-earlier level. In terms of earnings, the segment loss improved slightly to ¥33 million from ¥34 million a year earlier owing to the continued effect of expense reductions.」

「In terms of earnings, the segment loss improved to ¥19 million from ¥24 million a year earlier as higher revenue and continued efforts to improve the earnings structure through expense reductions and other measures took effect.」

「Revenue ¥38 million (103.9% year on year) Segment loss ¥9 million (segment loss of ¥11 million in the year-earlier period)」

「In terms of earnings, gross profit increased as the number of inventory items subject to write-downs declined and the sales mix shifted toward the company's own products. As a result of efforts to reduce fixed costs, the segment loss improved by ¥32 million from the previous fiscal year to ¥51 million.」

「Third-quarter revenue rose to ¥105 million, or 106.9% of the year-earlier level. Supported by higher revenue and the continued effect of expense reductions, the segment loss improved to ¥34 million from ¥53 million a year earlier.」

「Second-quarter revenue declined to ¥68 million, or 94.4% of the year-earlier level. However, the segment loss improved to ¥24 million from ¥34 million a year earlier as the earnings structure continued to improve through expense reductions and other measures.」

「The market for supplements addressing women's health issues, known as the femcare market, has been expanding. By promoting the benefits of IT Hanabiratake to menopausal women and increasing OEM transactions from a year earlier, revenue rose to ¥36 million, or 106.6% of the year-earlier level. In terms of earnings, the segment loss narrowed from ¥19 million to ¥11 million as higher revenue and continued efforts to improve the earnings structure through expense reductions took effect.」

「In terms of earnings, the segment loss improved to ¥84 million from the previous fiscal year through efforts to reduce fixed costs and the streamlining of unprofitable businesses.」

「Following the sale of the mail-order business during the second quarter of the previous fiscal year and the narrowing of the product range in order to focus on developing the business as a raw-materials manufacturer, revenue declined to ¥99 million, or 63.0% of the year-earlier level. However, the segment loss improved to ¥53 million from ¥80 million a year earlier, owing to the streamlining of unprofitable businesses and other measures.」

「Following the sale of InterTrade Healthcare's mail-order business during the second quarter of the previous fiscal year, second-quarter revenue declined to ¥72 million, or 74.3% of the year-earlier level. However, the segment loss improved to ¥34 million from ¥61 million a year earlier, as the unprofitable division with a deteriorating earnings structure was divested.」

「Revenue declined to ¥34 million, or 62.8% of the same period of the previous year, due to the sale of the mail-order business during the second quarter of the previous fiscal year as the company focused on developing its business as an IT Hanabiratake manufacturer. On the profit-and-loss side, the segment loss improved from ¥30 million to ¥19 million as the company divested the business whose earnings structure had deteriorated and concentrated its management resources.」

「Revenue ¥193 million (65.8% of the previous fiscal year) Segment loss ¥118 million (segment loss of ¥167 million in the previous fiscal year)」

「Due to the sale of Intertrade Healthcare's mail-order business, third-quarter revenue was ¥157 million, or 70.2% of the same period of the previous year. On the profit-and-loss side, the segment loss improved to ¥80 million from the same period of the previous year as the company divested the business whose earnings structure had deteriorated and concentrated its management resources.」

「Following the sale of Intertrade Healthcare’s mail-order business in order to focus on developing the business as an “IT Hanabiratake” manufacturer, second-quarter net sales were ¥97 million, or 66.0% of the year-earlier period. However, separating the business with a deteriorating earnings structure and concentrating management resources led to a slight improvement in profitability, with the segment loss narrowing to ¥61 million from the previous year.」

「On the profit-and-loss side, the segment loss improved slightly because advertising and promotional expenses and other costs were reduced further.」

「Revenue ¥293 million (114.0% of the previous fiscal year) Segment loss ¥167 million (segment loss of ¥176 million in the previous fiscal year)」

「In terms of earnings, the segment loss declined as gross profit increased with the expansion of sales of “IT maitake”-related products and research and development expenses for “IT maitake” decreased from the same period of the previous year.」

「Revenue ¥147 million (114.9% of the same period of the previous year) Segment loss ¥65 million (segment loss of ¥103 million in the same period of the previous year)」

「In terms of earnings, the segment loss declined substantially as sales of maitake-related products expanded and research and development expenses related to “IT maitake” decreased from the same period of the previous year.」

「Revenue ¥257 million (94.5% of the previous fiscal year) Segment loss ¥176 million (segment loss of ¥424 million in the previous fiscal year)」

「On the profit-and-loss side, the segment loss narrowed due to an improved sales mix through the company's own products, a significant decrease in research and development expenses related to research on IT Hanabiratake, and the effect of an inventory write-down recorded in the same period of the previous year.」

「On the profit-and-loss side, the segment loss narrowed as a result of an improved sales mix through the company's own products and lower research and development expenses related to research on IT Hanabiratake compared with the same period of the previous year.」

「On the profit-and-loss side, the segment loss improved slightly because research and development expenses related to research on IT Hanabiratake decreased from the same period of the previous year.」

「On the profit-and-loss side, the segment loss was ¥424 million, reflecting higher upfront investment, including research and development expenses for joint research and the formulation of Hanabiratake products in the People's Republic of Bangladesh, as well as an inventory write-down during the fiscal year because raw-material sales did not progress as planned at the beginning of the year.」

「On the profit-and-loss side, the segment loss increased due to higher upfront investment, including research and development expenses for joint research and the formulation of Hanabiratake products in the People's Republic of Bangladesh, as well as an inventory write-down in the third quarter because raw-material sales did not progress as initially planned.」

「On the profit-and-loss side, the segment loss increased due to higher research and development expenses associated with industry-academia-government joint research with Tokyo Women's Medical University and the National Institute of Advanced Industrial Science and Technology, as well as upfront investment toward the formulation of Hanabiratake products in the People's Republic of Bangladesh.」

「Segment loss ¥66 million (segment loss of ¥55 million in the same period of the previous year)」

「Revenue ¥240 million (130.0% of the previous fiscal year)　　Segment loss ¥185 million (segment loss of ¥354 million in the previous fiscal year)」